Molecular MOLN 深 沪
交易中 10-06 10:19:45 美东时间
3.80
0.000
0.00%
华盛通- 最 高4.72
- 今 开3.91
- 成交量 762股
- 最 低 3.75
- 昨 收 3.80
- 总市值 1.23亿
- 52周最高 5.36
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.00
- 委 比 73.68%
- 总股本 3232.57万
- 历史最高 32.04
- 量 比 7.94
- 振 幅 25.53%
- 历史最低 0.00
- 每 手 1
- 风险率 0.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Panel Endorses GRAIL Galleri Cancer Screening Tool
The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test, moving it closer to official approval.
09-25 01:27
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.
09-24 02:09
EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola Test
Co-Diagnostics advances its Ebola testing capabilities, sending Bundibugyo virus test kits for evaluation and completing a new assay study.
07-28 19:41
10项研究，聚焦寡核苷酸研究新前沿
编者按：寡核苷酸药物已成为全球新药开发的重要热点，近年来在不同疾病多个领域获得快速应用。为帮助合作伙伴更高效地推动寡核苷酸药物从实验室走向临床，药明康德围绕寡核...
07-24 18:01
4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win
4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to an 87% cut in treatment burden.
07-20 21:05
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
Molecular Partners and Orano Med announce the development of MP0726, a Radio-DARPin targeting mesothelin (MSLN) for ovarian cancer treatment. Preclinical data show promising tumor accumulation and biodistribution, selective binding to membrane-bound MSLN, and a favorable tumor to kidney ratio. This collaboration aims to address unmet medical needs in cancer therapy.
2025-06-22 20:00
Moleculin Announces $5.9 Million Public Offering
Moleculin Biotech announced a public offering of 16 million shares and Series E warrants to raise $5.9 million. Funds will be used to advance Annamycin and other drug pipelines through clinical development and preclinical studies. The company is currently conducting the MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia (AML) and expects the offering to close on June 23, 2025.
2025-06-20 13:20
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
Positive phase 1/2a trial data for MP0533 shows 3 of 8 relapsed/refractory AML patients achieved response in first cycle, including one with ongoing response beyond 6 months. Dose optimization continues in cohort 9 with faster administration for better therapeutic exposure, with results expected in H2 2025.
2025-06-11 20:00
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
Molecular Partners AG has conducted a strategic review to streamline operations, reducing its workforce by up to 40 positions (~24%) to enhance efficiency. This restructuring aims to focus on advancing clinical assets MP0533 and MP0712, with clinical milestones anticipated in H2 2025. The cash runway is now expected to extend into 2028, supporting ongoing development and new product pipelines. The company maintains its previously announced timelines for clinical data.
2025-06-10 05:00
